AlloVir has entered into a definitive agreement for the acquisition of the complete outstanding shares of Kalaris ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related ...

Shares of AlloVir tumbled in premarket trading Friday after the immunotherapy company said it has agreed to an all-stock reverse merger with clinical-stage biopharmaceutical company Kalaris ...

AlloVir (ALVR) stock falls as comany agrees to an all-stock merger transaction with Kalaris Therapeutics. Read more here.

Allovir Inc., which has struggled since late last December, will merge with privately held Kalaris Therapeutics Inc. to develop therapies for treating neovascular and exudative retinal diseases.

AlloVir (ALVR) announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock ...

Nov. 08, 2024 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR) today announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics (“Kalaris”) in an all ...